Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624007 | 0.78 | MOGAT2 (0.30) | — | |
| SCHEMBL21636304 | 0.78 | ALDH1A1 (0.42) | CES1PDE7AALDH1A1 | |
| SCHEMBL29821340 | 0.78 | ALDH1A1 (0.42) | CES1PDE7AALDH1A1 | |
| SCHEMBL30559943 | 0.77 | CES1 (0.38) | CES1PDE7AALDH1A1RAD52 | |
| SCHEMBL21624055 | 0.77 | CES1 (0.38) | CES1PDE7AALDH1A1RAD52 | |
| SCHEMBL30559945 | 0.77 | CES1 (0.45) | CES1PDE7AALDH1A1 | |
| SCHEMBL21624183 | 0.77 | CES1 (0.45) | CES1PDE7AALDH1A1 | |
| SCHEMBL21636315 | 0.70 | ALOX5 (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL11511830 | 0.66 | CES1 (0.39) | CES1PDE7AALDH1A1TDP1L3MBTL1 | |
| SCHEMBL21624018 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112673009-B | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3823971-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünethal GmbH (DE) | 2021-05-13 | — | — | US | disclosed |
| CN-112673009-A | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | CES1 1239/4885PDE7A 1051/4885ALDH1A1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.